CA3068387A1 - T cell compositions for immunotherapy - Google Patents

T cell compositions for immunotherapy Download PDF

Info

Publication number
CA3068387A1
CA3068387A1 CA3068387A CA3068387A CA3068387A1 CA 3068387 A1 CA3068387 A1 CA 3068387A1 CA 3068387 A CA3068387 A CA 3068387A CA 3068387 A CA3068387 A CA 3068387A CA 3068387 A1 CA3068387 A1 CA 3068387A1
Authority
CA
Canada
Prior art keywords
cells
cell
antigens
antigen
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3068387A
Other languages
English (en)
French (fr)
Inventor
Alfred E. Slanetz
Terry Y. Nakagawa
Marissa A. HERRMAN
Original Assignee
GENEIUS BIOTECHNOLOGY Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GENEIUS BIOTECHNOLOGY Inc filed Critical GENEIUS BIOTECHNOLOGY Inc
Publication of CA3068387A1 publication Critical patent/CA3068387A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA3068387A 2016-06-28 2017-06-28 T cell compositions for immunotherapy Pending CA3068387A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662355506P 2016-06-28 2016-06-28
US201662355533P 2016-06-28 2016-06-28
US201662355458P 2016-06-28 2016-06-28
US62/355,458 2016-06-28
US62/355,533 2016-06-28
US62/355,506 2016-06-28
PCT/US2017/039846 WO2018005712A1 (en) 2016-06-28 2017-06-28 T cell compositions for immunotherapy

Publications (1)

Publication Number Publication Date
CA3068387A1 true CA3068387A1 (en) 2018-01-04

Family

ID=60787739

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3068387A Pending CA3068387A1 (en) 2016-06-28 2017-06-28 T cell compositions for immunotherapy

Country Status (11)

Country Link
US (2) US20200237819A1 (https=)
EP (1) EP3487990A4 (https=)
JP (3) JP7034955B2 (https=)
KR (1) KR20190037243A (https=)
CN (1) CN109715788A (https=)
AU (3) AU2017290119A1 (https=)
CA (1) CA3068387A1 (https=)
IL (1) IL263896A (https=)
MX (1) MX2019000180A (https=)
SG (1) SG11201811745UA (https=)
WO (1) WO2018005712A1 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102625832A (zh) 2009-08-24 2012-08-01 贝勒医学院 产生对多种肿瘤抗原或多种病毒特异的ctl细胞系
ES2748652T3 (es) 2012-02-09 2020-03-17 Baylor College Medicine Mezclas pep para generar CTL multivíricos con amplia especificidad
US20180072990A1 (en) * 2015-03-20 2018-03-15 Children's National Medical Center Generating virus or other antigen-specific t cells from a naïve t cell population
HUE066460T2 (hu) 2016-10-26 2024-08-28 Iovance Biotherapeutics Inc A kriokonzervált tumor infiltráló limfociták restimulációja
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
KR102618948B1 (ko) 2016-11-17 2023-12-27 이오반스 바이오테라퓨틱스, 인크. 잔유 종양 침윤 림프구 및 그의 제조 및 사용 방법
CA3049165A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
CN110199017A (zh) 2017-01-20 2019-09-03 国立大学法人京都大学 CD8α+β+细胞毒性T细胞的制备方法
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
TW201930340A (zh) * 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
EP3737743A1 (en) 2018-01-08 2020-11-18 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
WO2019217753A1 (en) 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JP7198602B2 (ja) * 2018-07-11 2023-01-04 カワサキモータース株式会社 自動二輪車
EP3831936A4 (en) * 2018-07-31 2022-04-13 Thyas Co. Ltd. METHOD FOR PRODUCING A REGENERATED T LYMPHOCYTE POPULATION USING IPS CELLS
AU2019314888A1 (en) * 2018-07-31 2021-02-18 Polybiocept Gmbh Production and selection of tumor uber reactive immune cells (TURICs)
JP2021533759A (ja) * 2018-08-10 2021-12-09 ユーティレックス カンパニー リミテッド 癌抗原特異的ｃｄ８＋ｔ細胞を調製および凍結保存するための方法
EP3834833A4 (en) * 2018-08-10 2022-05-18 Eutilex Co., Ltd. CANCER ANTIGEN-SPECIFIC CYTOTOXIC T-CELLS
JP7632868B2 (ja) * 2018-10-26 2025-02-19 国立大学法人信州大学 高効率な遺伝子改変細胞の作製方法
EP3873540A4 (en) 2018-10-31 2022-07-27 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
WO2020092839A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
MY210603A (en) 2018-11-05 2025-10-01 Iovance Biotherapeutics Inc Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
US12611427B2 (en) 2018-11-05 2026-04-28 Iovance Biotherapeutics, Inc. Treatment of NSCLC patients refractory for anti-PD-1 antibody
WO2020102701A1 (en) * 2018-11-16 2020-05-22 Rapa Therapeutics, Llc Methods for the manufacture of th1/tc1 phenotype t cells
US20220064597A1 (en) * 2018-12-18 2022-03-03 Beth Israel Deaconess Medical Center, Inc. Generation of organoid-primed T (opT) cells with memory phenotype
WO2020146434A2 (en) * 2019-01-07 2020-07-16 Children's National Medical Center Ex vivo activated t-lymphocytic compositions and methods of using the same
JP7649244B2 (ja) * 2019-02-14 2025-03-19 リサーチ インスティテュート アット ネイションワイド チルドレンズ ホスピタル 免疫細胞の効力をアッセイするための刺激剤の使用
JP7668226B2 (ja) * 2019-03-30 2025-04-24 ビオンテック ユーエス インコーポレイテッド Ｔ細胞組成物を調製するための組成物および方法、ならびにそれらの使用
WO2020210630A1 (en) 2019-04-12 2020-10-15 C4 Therapeutics, Inc. Tricyclic degraders of ikaros and aiolos
EP3976068A4 (en) * 2019-05-31 2023-08-09 Children's National Medical Center CYTOKINE COCKTAILS FOR SELECTIVE T-LYMPHOCYTE SUBSET EXPANSION
WO2020263919A1 (en) * 2019-06-24 2020-12-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. A peptide-based screening method to identify neoantigens for use with tumor infiltrating lymphocytes
JP7337373B2 (ja) * 2019-07-29 2023-09-04 サイアス株式会社 抗原特異的ｔ細胞の製造方法
CN114615886A (zh) * 2019-08-29 2022-06-10 得克萨斯大学体系董事会 细胞冷冻保存培养基
US20230032934A1 (en) * 2019-11-27 2023-02-02 Myst Therapeutics, Llc Method of producing tumor-reactive t cell composition using modulatory agents
EP4081226A4 (en) * 2019-12-23 2024-03-27 Baylor College of Medicine T CELL PERFORMANCE ASSAY AS A PROGNOSIS FACTOR FOR CLINICAL OUTCOME
US12378521B2 (en) 2020-04-15 2025-08-05 Amgen Inc. Method for enhancing production of genetically engineered autologous T cells
US12241086B2 (en) 2020-04-15 2025-03-04 Amgen Inc. Process for generating genetically engineered autologous T cells
JP2023546359A (ja) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
WO2022115641A2 (en) * 2020-11-25 2022-06-02 Geneius Biotechnology, Inc. Antigen specific t cells and methods of making and using same
JP2024512029A (ja) 2021-03-25 2024-03-18 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｔ細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用
CN113512529B (zh) * 2021-07-21 2022-11-25 上海赛傲生物技术有限公司 特异性抗病毒过继免疫细胞ab的制备方法
CN113564116B (zh) * 2021-07-21 2023-08-01 北京赛傲生物技术有限公司 特异性抗病毒过继免疫细胞ce的制备方法
CN113481157B (zh) * 2021-07-21 2023-03-17 上海赛傲生物技术有限公司 特异性抗病毒过继免疫细胞的优化制备方法
US20250130220A1 (en) * 2021-09-08 2025-04-24 KSQ Therapeutics, Inc. Lymphocyte potency assay
EP4412628A1 (en) * 2021-10-08 2024-08-14 Baylor College of Medicine Targeting common somatic mutations in breast cancer with neo-antigen specific adoptive t cell therapy
JP2023064787A (ja) * 2021-10-27 2023-05-12 国立大学法人京都大学 Ｔ細胞の品質評価方法、および当該方法に用いる試薬
US20250223552A1 (en) * 2022-03-18 2025-07-10 St. Jude Children's Research Hospital, Inc. Method for preparing t cells for adoptive t cell therapy
JP2025512401A (ja) 2022-04-15 2025-04-17 アイオバンス バイオセラピューティクス，インコーポレイテッド 特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス
KR102566680B1 (ko) * 2022-09-28 2023-08-14 (주)포에버엔케이 면역세포 및 자연살해세포 배양을 위한 신규한 이중배양 제조방법 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU765085B2 (en) * 1998-05-11 2003-09-11 Miltenyi Biotec Gmbh Method of direct selection of antigen-specific T cells
WO2004015070A2 (en) 2002-08-08 2004-02-19 Baylor College Of Medicine Isolation and identification of t cells
ES2532896T5 (es) 2008-05-14 2018-03-20 Immatics Biotechnologies Gmbh Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
CN102625832A (zh) 2009-08-24 2012-08-01 贝勒医学院 产生对多种肿瘤抗原或多种病毒特异的ctl细胞系
US9114100B2 (en) * 2010-05-17 2015-08-25 Duke University Methods of treatment using ex vivo expansion of cord blood T cells
AU2012258603A1 (en) * 2011-05-26 2014-01-16 Geneius Biotechnology, Inc. Modulated immunodominance therapy
US10316289B2 (en) 2012-09-06 2019-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T memory stem cell populations
CN106687584B (zh) * 2014-09-04 2021-08-13 干细胞技术公司 用于t细胞或nk细胞活化和扩增的可溶性抗体复合物
EP3234130B1 (en) * 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
HK1255161A1 (zh) * 2015-07-15 2019-08-09 Juno Therapeutics, Inc. 用於过继性细胞治疗的工程细胞

Also Published As

Publication number Publication date
KR20190037243A (ko) 2019-04-05
IL263896A (en) 2019-01-31
JP2022066355A (ja) 2022-04-28
AU2023254998A1 (en) 2023-11-16
SG11201811745UA (en) 2019-01-30
JP2019519246A (ja) 2019-07-11
US20230145991A1 (en) 2023-05-11
JP7034955B2 (ja) 2022-03-14
EP3487990A1 (en) 2019-05-29
EP3487990A4 (en) 2020-07-29
WO2018005712A1 (en) 2018-01-04
US20200237819A1 (en) 2020-07-30
AU2026202260A1 (en) 2026-04-09
CN109715788A (zh) 2019-05-03
MX2019000180A (es) 2019-11-05
JP2024103547A (ja) 2024-08-01
AU2017290119A1 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
US20230145991A1 (en) T cell compositions for immunotherapy
JP7423684B2 (ja) 免疫細胞を操作するための抗原提示足場
Buchholz et al. T cell fate at the single-cell level
Withers et al. Establishment and operation of a third-party virus-specific T cell bank within an allogeneic stem cell transplant program
EP2899269B1 (en) Method for cloning t cell receptor
JP5840857B2 (ja) 細胞傷害性ｔ細胞誘導用組成物
TW201625800A (zh) 選擇用於過繼性細胞療法之ｔ細胞株及其供體之方法
Janelle et al. Defining novel parameters for the optimal priming and expansion of minor histocompatibility antigen-specific T cells in culture
US20240263136A1 (en) Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same
Gary et al. Clinical-grade generation of peptide-stimulated CMV/EBV-specific T cells from G-CSF mobilized stem cell grafts
KR102859043B1 (ko) 면역 세포 조작을 위한 안정화된 mhc 분자가 있는 스캐폴드
Hasan et al. A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy
Provenzano et al. Identification of immune dominant cytomegalovirus epitopes using quantitative real-time polymerase chain reactions to measure interferon-γ production by peptide-stimulated peripheral blood mononuclear cells
TW202242097A (zh) 經工程化之抗原呈現細胞
CA3169995A1 (en) Pharmaceutical composition and method for inducing an immune response
Kircher et al. Hematopoietic lineage-restricted minor histocompatibility antigen HA-1 in graft-versus-leukemia activity after donor lymphocyte infusion
US20240252644A1 (en) Person-tailored t cell composition targeting merkel cell carcinoma
KR20120054018A (ko) 일과성 생착 ｃｔｌ을 포함하는 의약품 조성물
Berger et al. A non‐human primate model for analysis of safety, persistence, and function of adoptively transferred T cells
WO2017156365A1 (en) Methods of generating antigen-specific t cells for adoptive immunotherapy
Hasan et al. Artificial antigen presenting cells that express prevalent HLA alleles: A step towards the broad application of antigen-specific adoptive cell therapies
Kammula et al. Use of high throughput qPCR screening to rapidly clone low frequency tumour specific T-cells from peripheral blood for adoptive immunotherapy
Grube et al. An APC for every occasion: induction and expansion of human Ag-specific CD4 and CD8 T cells using cellular and non-cellular APC
Meckiff Evolution of the human CD4+ T cell response to Epstein-Barr virus infection-analysis of systemic and local immune responses
Huisman et al. Short summary

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220506

C11 Application revival requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED

Effective date: 20240918

C11 Application revival requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED

Effective date: 20241108

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250128

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250618

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250618

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260106